On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), marking the first broad-spectrum RAS(ON) inhibitor approved for adults with metastatic pancreatic ductal adenocarcinoma (PDAC). The regulatory milestone was cleared a remarkable 6.5 months ahead of its standard user-fee goal date under the FDA Commissioner's National Priority Voucher (CNPV) pilot program, supported by Breakthrough Therapy, Orphan Drug, and Priority Review designations, as well as an international review through Project Orbis alongside Health Canada.
Across clinical trial readouts—most notably the late-breaking presentation at the ASCO 2026 Annual Meeting—oncology teams focused on the overall survival hazard ratio in previously treated patients. For pharmacy and therapeutics (P&T) committees, oncology medical directors, and specialty pharmacy access teams, the commercial and formulary reality is shaped by the posted label:
Does the August 26 label require a companion diagnostic test for specific RAS mutations, does the indication phrase "or who are not candidates for multiagent systemic therapy" create automatic first-line coverage, and how does this oral 300 mg daily tablet interact with traditional infusional chemotherapy under medical benefit?
The direct answers establish critical boundaries for oncology access:
- No companion diagnostic is required by the FDA label. Unlike allele-specific KRAS inhibitors, Rasonque's indication does not restrict use to a companion-diagnostic result. RASolute 302 required local documentation of RAS mutation status (mutant or wild-type) and showed statistically significant overall survival in both the RAS G12 population and the overall population, which included patients without a RAS mutation detected by local testing. That is a labeling choice, not a prohibition on a plan requiring mutation documentation as a medical-policy edit.
- The pivotal trial is previously treated, ECOG 0–1 disease. RASolute 302 randomized 500 adults with metastatic pancreatic adenocarcinoma after one prior fluoropyrimidine- or gemcitabine-based line. Section 14 of the posted prescribing information is that 2L trial. The indication sentence also covers adults who are not candidates for multiagent systemic therapy, but the label does not present a dedicated first-line-ineligible efficacy cohort. First-line claims that rest only on that clause should expect documentation friction.
- The 300 mg once-daily oral regimen shifts the claim onto pharmacy benefit. Investigator's-choice comparators in RASolute 302 were intravenous regimens (mFOLFIRINOX, gemcitabine plus nab-paclitaxel, FOLFOX, or nal-IRI plus 5-FU/leucovorin) billed under medical benefit. Rasonque is supplied as 100 mg and 150 mg tablets for a 300 mg daily dose and is dispensed through specialty pharmacy, which puts Medicare patients on Part D specialty-tier cost-sharing rather than Part B buy-and-bill.
- CNPV compressed the payer calendar. As detailed in our analysis of the FDA Commissioner's National Priority Voucher pilot program, voucher-assisted reviews shorten standard clocks. FDA states this application was approved about 6.5 months before the user-fee goal date, so many plans will still be writing medical policy after the product is orderable.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ RASONQUE (DARAXONRASIB) REGULATORY & ACCESS SCORECARD │
├──────────────────────────┬───────────────────────────────────────────────────────────────────┤
│ Metric / Dimension │ Labeled Fact / Operational Status │
├──────────────────────────┼───────────────────────────────────────────────────────────────────┤
│ FDA Action Date │ August 26, 2026 (New Molecular Entity) │
│ Approved Dosage & Form │ 300 mg orally once daily from 100 mg and 150 mg tablets; ± food │
│ Labeled Indication │ Adults with metastatic PDAC after ≥1 prior systemic therapy, OR │
│ │ in patients who are not candidates for multiagent systemic therapy│
│ Companion Diagnostic │ Not required by FDA label; dual G12 & ITT efficacy established │
│ Review Mechanisms │ CNPV (6.5 mos early), Breakthrough, Orphan, Priority, Orbis │
│ Pivotal Trial │ RASolute 302 (NCT06625320); 500 randomized 1:1 (N=248 vs N=252) │
│ ITT Median OS │ 13.2 mos vs. 6.7 mos (HR 0.40; 95% CI: 0.30, 0.53; p < 0.0001) │
│ ITT Median PFS │ 7.2 mos (5.7, 7.5) vs. 3.6 mos (2.9, 4.2); HR 0.49 (0.38, 0.64) │
│ ITT Confirmed ORR │ 30% (95% CI: 25, 36) vs. 11% (95% CI: 7, 15) │
│ Primary Benefit Channel │ Pharmacy Benefit (Specialty Pharmacy limited distribution) │
│ Key Warnings │ Dermatologic (86%), Stomatitis (57%), Diarrhea (63%), ILD, GI Perf│
└──────────────────────────┴───────────────────────────────────────────────────────────────────┘
Below, we analyze the official FDA Oncology Center of Excellence (OCE) dataset, examine the dual RAS G12 and ITT analyses, dissect the operational friction in the "multiagent-ineligible" indication clause, and provide a formulary roadmap for health plans and specialty pharmacies.
Approved Indication and the Companion Diagnostic Decision
The approved indication for Rasonque defines two clinical pathways for adult metastatic pancreatic adenocarcinoma:
"RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy."
Why No Companion Diagnostic Was Mandated
In precision oncology, targeted small molecules directed against oncogenic drivers—such as EGFR inhibitors in non-small cell lung cancer or BRAF inhibitors in melanoma—are almost universally paired with FDA-approved companion diagnostic (CDx) assays (e.g., tissue NGS, PCR, or liquid biopsy) that restrict coverage strictly to patients with verified somatic mutations.
For Rasonque, FDA approved the application without a companion diagnostic requirement. Two facts in the posted label explain that choice without proving equal benefit in RAS-wild-type tumors:
- Mechanism and epidemiology: Daraxonrasib is a RAS(ON) multi-selective inhibitor. The FDA press notes that RAS is a key driver in most pancreatic adenocarcinoma, and NCI figures cited there put adenocarcinoma at 90% to 95% of about 67,000 U.S. pancreatic cancer cases per year.
- Dual statistical testing in RASolute 302: Major efficacy outcomes were OS and BICR-assessed PFS in the RAS G12 population, with additional OS, PFS, and ORR analyses in the overall population. Because the overall population also won, the indication does not require an approved CDx. Local RAS status was still collected: 92% of randomized patients had KRAS G12 mutations, 5% had KRAS mutations at other locations (G13 or Q61), and 3% had no RAS mutation detected by local testing. An ITT win is not a RAS-wild-type subgroup proof.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ RASONQUE TESTING & ELIGIBILITY DECISION FRAMEWORK │
├──────────────────────────────────────────────────────────────────────────────────────────────┤
│ │
│ [ Adult Metastatic PDAC Patient ] │
│ │ │
│ ▼ │
│ [ Prior Systemic Therapy History ] │
│ │ │
│ ┌──────────────────┴──────────────────┐ │
│ ▼ ▼ │
│ [ ≥1 Prior Systemic Line ] [ Treatment-Naive Patient ] │
│ (FOLFIRINOX, Gem/Nab-Pac, etc.) │ │
│ │ ▼ │
│ │ [ Multiagent Chemo Candidate? ] │
│ │ │ │
│ │ ┌─────────────┴─────────────┐ │
│ │ ▼ ▼ │
│ │ [ Yes ] [ No ] │
│ │ (Standard 1L Chemo) (Documented Contraindication │
│ │ (FOLFIRINOX/NALIRIFOX) ECOG PS ≥2, Organ Impairment) │
│ │ │ │ │
│ ▼ │ ▼ │
│ ┌──────────────────────┐ │ ┌──────────────────────┐ │
│ │ On-Label Standard 2L │ │ │ On-Label Special 1L │ │
│ │ • No CDx Required │ │ │ • Broad Label Clause │ │
│ │ • RASolute 302 Data │ │ │ • High PA Friction │ │
│ │ • High Approval Rate │ │ │ • Section 14 2L Gap │ │
│ └──────────────────────┘ │ └──────────────────────┘ │
│ ▼ │
│ [ Routine 1L Chemo Start ] │
│ │
└──────────────────────────────────────────────────────────────────────────────────────────────┘
Epidemiology Denominator Differences
In regulatory review documents and public communications, epidemiology estimates diverge slightly between agency publications and sponsor materials:
- FDA / NCI Estimate: The FDA press release cites National Cancer Institute (NCI) surveillance estimates of approximately 67,000 new pancreatic cancer cases diagnosed annually in the United States, of which 90% to 95% are adenocarcinoma.
- Sponsor Estimate: Revolution Medicines public filings cite approximately 55,000 PDAC diagnoses in the U.S. per year.
P&T dossiers should document both figures: the 67,000 figure represents all pancreatic malignancies (including endocrine and cystic tumors), whereas the 55,000 figure isolates histologically confirmed ductal adenocarcinomas.
RASolute 302 Deep Dive: Primary Data and P&T Dossier Evidence
The registrational evidence supporting Rasonque comes from RASolute 302 (NCT06625320), a randomized, open-label, multicenter trial in 500 adults with metastatic pancreatic adenocarcinoma and disease progression after one prior fluoropyrimidine- or gemcitabine-based line. Patients needed ECOG performance status 0 or 1 and local documentation of RAS mutation status (mutant or wild-type).
Patients were randomized 1:1 to:
- Rasonque: 300 mg orally once daily until disease progression or unacceptable toxicity (N = 248); or
- Physician's-choice chemotherapy: mFOLFIRINOX, gemcitabine plus nab-paclitaxel, FOLFOX, or nal-IRI plus 5-FU/leucovorin (N = 252).
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ RASOLUTE 302 (NCT06625320) PIVOTAL EFFICACY RESULTS: ITT POPULATION │
├─────────────────────────────────────┬──────────────────────┬──────────────────┬──────────────┤
│ Efficacy Parameter │ Rasonque (300 mg QD) │ Physician's-Choice Chemo │ Hazard Ratio │
│ │ (N = 248) │ (N = 252) │ (95% CI) │
├─────────────────────────────────────┼──────────────────────┼──────────────────┼──────────────┤
│ Median Overall Survival (OS) │ 13.2 months │ 6.7 months │ HR = 0.40 │
│ 95% Confidence Interval │ (10.0, NE) │ (5.8, 8.0) │ (0.30, 0.53) │
│ Stratified Log-Rank p-value │ p < 0.0001 │ — │ — │
├─────────────────────────────────────┼──────────────────────┼──────────────────┼──────────────┤
│ Median Progression-Free Survival │ 7.2 months │ 3.6 months │ HR = 0.49 │
│ 95% Confidence Interval │ (5.7, 7.5) │ (2.9, 4.2) │ (0.38, 0.64) │
├─────────────────────────────────────┼──────────────────────┼──────────────────┼──────────────┤
│ Confirmed Overall Response Rate │ 30% │ 11% │ p < 0.0001 │
│ 95% Confidence Interval │ (25, 36) │ (7, 15) │ — │
└─────────────────────────────────────┴──────────────────────┴──────────────────┴──────────────┘
Statistical Strength in the 2L Setting
The magnitude of the survival advantage in the overall RASolute 302 population is large for previously treated metastatic pancreatic adenocarcinoma:
- Overall survival: Median OS doubled from 6.7 months to 13.2 months (HR 0.40; 95% CI 0.30, 0.53; p < 0.0001).
- Progression-free survival: Median PFS was 7.2 months (95% CI 5.7, 7.5) versus 3.6 months (95% CI 2.9, 4.2) (HR 0.49; 95% CI 0.38, 0.64; p < 0.0001).
- Objective response: Confirmed ORR was 30% (95% CI 25, 36) versus 11% (95% CI 7, 15).
Those ITT figures are the numbers to quote first. The RAS G12 analysis (n = 459) is the other labeled pair: median OS 13.2 versus 6.6 months (HR 0.40; 95% CI 0.30, 0.54); median PFS 7.3 versus 3.5 months (HR 0.45; 95% CI 0.34, 0.59); ORR 32% (26, 38) versus 11% (7, 16). Do not substitute the G12 chemo median of 6.6 months for the overall-population 6.7 months.
The "Multiagent-Ineligible" Clause: Clinical Intent vs. Payer Scrutiny
While the second-line data from RASolute 302 is unequivocal, the second half of the indication statement creates significant administrative and formulary complexity:
"...or who are not candidates for multiagent systemic therapy."
Why the Clause Exists
In oncology practice, some newly diagnosed metastatic PDAC patients cannot receive aggressive multiagent regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel because of performance status, organ impairment, or comorbidities. The labeled clause gives clinicians an on-label sentence for those patients. It is not a trial cohort.
The Access Gap in Section 14
Section 14 is RASolute 302: previously treated, ECOG 0 or 1, one prior systemic line. It does not contain a randomized first-line-ineligible dataset.
Payers writing utilization management will likely split the indication:
- Prior-line claims: Documentation of progression after a fluoropyrimidine- or gemcitabine-based regimen matches the trial.
- First-line ineligibility claims: Expect requests for why multiagent chemotherapy is not appropriate. Do not treat unpublished ECOG, creatinine, or bilirubin cutoffs as if they were already in a national policy. The trial itself required ECOG 0 or 1, so a first-line frail-patient request is outside the Section 14 population even when the indication sentence is broader.
CNPV Pilot Mechanics: 6.5-Month Acceleration and the Access Clock
Rasonque represents one of the most visible uses of the FDA Commissioner's National Priority Voucher (CNPV) pilot. FDA states the application was approved approximately 6.5 months ahead of the user-fee goal date, under Breakthrough Therapy, Orphan Drug, Priority Review, and CNPV.
Expedited review does not by itself write coverage:
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ CNPV EXPEDITED LAUNCH ACCESS TIMELINE │
├──────────────────────────────────────────────────────────────────────────────────────────────┤
│ │
│ Day 0 (Aug 26) ────► Days 1–30 ────► Days 31–90 ────► Days 91–180 │
│ FDA Approval Commercial Supply Interim PA Period Formal P&T Review │
│ (6.5 mos early) Hub Intake Active Manual Medical Review Published Criteria │
│ No DailyMed SPL Specialty Pharmacy Part D Tiering │
│ No DAF ApplNo Coverage Exceptions EHR Order Sets │
│ │
└──────────────────────────────────────────────────────────────────────────────────────────────┘
- DailyMed and Structured Product Labeling (SPL) Lag: Under 21 CFR 201/314, manufacturers have 14 days following approval to transmit electronic SPL data to DailyMed. As of August 29, 2026, DailyMed returns zero results for daraxonrasib. Prescribers and specialty pharmacies must rely on the FDA OCE web posting and manufacturer prescribing information.
- Interim exception workflows: New oral oncology agents often sit in non-formulary or PA-required status until a quarterly P&T cycle. Specialty pharmacy hubs should keep packets that quote the FDA OCE page and the posted prescribing information rather than ASCO slides.
- Project Orbis is not foreign approval: FDA collaborated with Health Canada. EMA and PMDA were observers. Observer status is not authorization in those jurisdictions.
Benefit Channel Crosswalk: Oral Pharmacy Benefit vs. Infusional Chemo
The transition from IV chemotherapy to oral daraxonrasib fundamentally alters the reimbursement workflow for oncology clinics:
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ REIMBURSEMENT & BENEFIT CHANNEL CROSSWALK │
├──────────────────────────┬──────────────────────────────┬────────────────────────────────────┤
│ Feature / Dimension │ Standard 2L IV Regimens │ Rasonque (Daraxonrasib 300 mg) │
├──────────────────────────┼──────────────────────────────┼────────────────────────────────────┤
│ Route of Administration │ Intravenous infusion │ Oral tablet (once daily) │
│ Primary Benefit Channel │ Medical Benefit │ Pharmacy Benefit │
│ Reimbursement Model │ Buy-and-bill (ASP + 6%) │ PBM Specialty Pharmacy fulfillment │
│ Coding Infrastructure │ HCPCS J-codes + CPT 96413 │ National Drug Code (NDC) │
│ Patient Cost-Sharing │ 20% Part B (covered by │ Part D specialty tier coinsurance │
│ │ supplemental/Medigap) │ (subject to $2,000 out-of-pocket) │
│ Dispensing Channel │ Hospital Infusion / OCM │ Limited Distribution Network (LDN) │
│ Adherence / Refill Mgmt │ Chair-time attendance │ Hub outreach, monthly refill checks│
└──────────────────────────┴──────────────────────────────┴────────────────────────────────────┘
Medicare Part D IRA Cap Protection
Under the Inflation Reduction Act redesign of Medicare Part D, an annual out-of-pocket cap (set at $2,000 when the redesign took effect in 2025) limits Medicare patient exposure for oral oncolytics relative to the prior catastrophic coinsurance design. That cap is a benefit-design fact, not a coverage determination for Rasonque.
Commercial copay cards, if used, are not coverage, and accumulator or maximizer programs can still leave a residual patient bill.
Safety Profile, Labeled Warnings, and Toxicity Management
While Rasonque avoids the severe hematologic myelosuppression (neutropenic fever, grade 4 thrombocytopenia) and alopecia characteristic of cytotoxic chemotherapy, its mechanism of multi-RAS inhibition generates a distinct spectrum of toxicities that require active specialty pharmacy monitoring:
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ RASONQUE SAFETY WARNINGS & CLINICAL TRIAL INCIDENCE │
├─────────────────────────────────────┬──────────────────────┬─────────────────────────────────┤
│ Labeled Warning / Adverse Reaction │ Trial Frequency (All)│ Grade ≥3 / Clinical Management │
├─────────────────────────────────────┼──────────────────────┼─────────────────────────────────┤
│ Dermatologic Toxicity │ 86% │ 10% Grade 3; rash, dermatitis │
│ (Rash, dry skin, pruritus) │ │ Prophylactic emollients/steroids│
├─────────────────────────────────────┼──────────────────────┼─────────────────────────────────┤
│ Diarrhea │ 63% │ 6% Grade 3; oral rehydration, │
│ │ │ loperamide, dose reduction │
├─────────────────────────────────────┼──────────────────────┼─────────────────────────────────┤
│ Stomatitis & Oral Disorders │ 57% │ 9% Grade 3; dexamethasone mouth │
│ │ │ rinse, dose hold/reduction │
├─────────────────────────────────────┼──────────────────────┼─────────────────────────────────┤
│ Interstitial Lung Disease (ILD) │ 2.4% │ 1 fatal case; permanent │
│ / Pneumonitis │ │ discontinuation for any ILD │
├─────────────────────────────────────┼──────────────────────┼─────────────────────────────────┤
│ Gastrointestinal Perforation │ 0.9% │ 1 fatal case; permanent │
│ │ │ discontinuation if confirmed │
├─────────────────────────────────────┼──────────────────────┼─────────────────────────────────┤
│ Treatment Discontinuation Rate │ 2.9% │ Permanent discontinuations due │
│ │ │ to drug-related adverse events │
└─────────────────────────────────────┴──────────────────────┴─────────────────────────────────┘
Specialty Pharmacy Care Management Priorities
Labeled warnings drive monitoring more than OS headlines:
- Skin and stomatitis: Dermatologic toxicity 86% (10% Grade 3) and stomatitis 57% (9% Grade 3) in pancreatic adenocarcinoma trials. The PI recommends prophylactic dermatologic measures at initiation.
- Diarrhea: 63% (6% Grade 3). The label says to treat as clinically indicated and to withhold, reduce, or discontinue by severity—not a patient loperamide protocol.
- ILD and GI perforation: 2.4% and 0.9% in those trials, each including a fatal event. New cough, dyspnea, or severe abdominal pain is a labeled reason to withhold and evaluate.
Dataset Census and Negative Controls
To maintain data integrity across regulatory repositories, our census cross-checked primary datasets as of August 29, 2026:
- FDA Orange Book: The official FDA Orange Book data files (products.txt, updated through August 14, 2026, comprising 48,664 product rows) show 0 product rows for daraxonrasib or Rasonque. This confirms that patent listings and therapeutic equivalence records for this August 26 approval will populate in the September monthly cumulative supplement.
- Drugs@FDA Relational Snapshot: The relational database snapshot (dated August 16, 2026) likewise contains 0 rows for daraxonrasib.
- Chemotherapy Floor Benchmark: Orange Book census identifies 88 product rows (41 prescription active rows) for generic gemcitabine hydrochloride across multiple ANDA sponsors, representing the ubiquitous low-cost generic baseline against which all metastatic PDAC regimens are measured.
Frequently Asked Questions
Do patients need a RAS mutation test before starting Rasonque?
No. The FDA-approved label does not require a companion diagnostic. RASolute 302 showed statistically significant OS and PFS in both the RAS G12 population and the overall population. Local RAS status was documented in the trial (92% KRAS G12, 5% other KRAS, 3% no RAS mutation detected). A plan can still ask for mutation documentation as a medical-policy edit; that is not the same as an FDA CDx requirement.
Did RASolute 302 enroll untreated patients who could not receive multiagent chemotherapy?
No. RASolute 302 enrolled adults with metastatic pancreatic adenocarcinoma after one prior systemic line, ECOG 0 or 1. The indication sentence also includes patients who are not candidates for multiagent chemotherapy, but Section 14 does not contain a dedicated first-line-ineligible randomized cohort. Expect documentation of why multiagent therapy is not appropriate.
Is this the same RMC-6236 voucher listed on the CNPV explainer?
Yes. Daraxonrasib was developed under the investigational designation RMC-6236. Revolution Medicines received a Commissioner's National Priority Voucher in October 2025, which enabled the company to submit the NDA under an accelerated review timetable, resulting in approval 6.5 months ahead of standard PDUFA timelines.
Can a hospital substitute gemcitabine for Rasonque on an Orange Book TE code?
No. Rasonque is a new chemical entity (novel small-molecule RAS inhibitor) with no therapeutic equivalents or generic formulations. Gemcitabine is a cytotoxic antimetabolite. There is no therapeutic equivalence relationship between the two drugs in the Orange Book.
Sources
- FDA Oncology Center of Excellence: FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma (Approval announcement, trial metrics, dosing, and Project Orbis details; August 26, 2026).
- U.S. Food and Drug Administration: FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer (Press release, CNPV pilot details, NCI incidence data, and regulatory review history; August 26, 2026).
- Revolution Medicines: RASONQUE (daraxonrasib) prescribing information (Indication, Section 14 Table 6 ITT and RAS G12 analyses, 100 mg/150 mg how-supplied, food language; Revised August 2026).
- Revolution Medicines: U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib) (No-CDx statement, RASolute 302 design, ISI safety frequencies, sponsor PDAC incidence about 55,000; August 26, 2026).
- National Institutes of Health / ClinicalTrials.gov: Study of Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (RASolute 302) (Registrational trial protocol, NCT06625320).
- U.S. Food and Drug Administration: Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Data files products.txt, patent.txt, and exclusivity.txt; August 2026 data release).
